Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Itacitinib - Incyte Corporation

Drug Profile

Itacitinib - Incyte Corporation

Alternative Names: IBI-377; INCB-039110; INCB-039110-adipate; INCB-39110; Itacitinib-adipate

Latest Information Update: 09 Dec 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Incyte Corporation
  • Developer AstraZeneca; Incyte Corporation
  • Class Acetonitriles; Anti-inflammatories; Antineoplastics; Antipsoriatics; Antirheumatics; Azetidines; Small molecules
  • Mechanism of Action Janus kinase 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Graft-versus-host disease
  • Phase II Hodgkin's disease; Myelofibrosis; Non-small cell lung cancer; Ulcerative colitis
  • Phase I/II Bronchiolitis obliterans; Haematological malignancies; Non-Hodgkin's lymphoma; Solid tumours
  • Phase I Malignant melanoma; Soft tissue sarcoma
  • Clinical Phase Unknown Aplastic anaemia
  • Discontinued Pancreatic cancer; Plaque psoriasis; Rheumatoid arthritis

Most Recent Events

  • 07 Dec 2019 Pharmacodynamics data from a preclinical trial in Cancer presented at the 61st Annual Meeting and Exposition of the American Society of Haematology (ASH-2019)
  • 16 Oct 2019 M.D. Anderson Cancer Center plans a phase II trial for Graft Versus Host Disease (Prevention) in USA in January 2020 (NCT04127721)
  • 30 Sep 2019 Phase-I clinical trials in Soft tissue sarcoma (Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (PO) (NCT03670069)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top